PVCT (Provectus Biopharmaceuticals) Net Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Provectus Biopharmaceuticals Net Margin %?

Provectus Biopharmaceuticals PVCT -4.00% Net Margin % is 0.00% as of Mar. 2026. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Provectus Biopharmaceuticals ranks worse than 105932.1% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Provectus Biopharmaceuticals's Net Income for the three months ended in Mar. 2026 was $-1.29 Mil. Provectus Biopharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Provectus Biopharmaceuticals's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Provectus Biopharmaceuticals's Net Margin % or its related term are showing as below:


PVCT's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.635
* Ranked among companies with meaningful Net Margin % only.

Provectus Biopharmaceuticals  (OTCPK:PVCT) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Provectus Biopharmaceuticals Net Margin % Related Terms

Provectus Biopharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals Net Margin % Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Provectus Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PVCT vs PSTV, ALGS, ATNM: Net Margin % Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provectus Biopharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's Net Margin % falls into.


Provectus Biopharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Provectus Biopharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.505/0
= %

Provectus Biopharmaceuticals's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.29/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Provectus Biopharmaceuticals (PVCT) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Provectus Biopharmaceuticals and its competitors. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry.
Is Provectus Biopharmaceuticals' Net Margin % too high?
Provectus Biopharmaceuticals' current Net Margin % is 0.00%. Based on the distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Provectus Biopharmaceuticals' Net Margin % compare to PSTV and ALGS?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 944 companies for Net Margin %. This places Provectus Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Provectus Biopharmaceuticals and its competitors. Provectus Biopharmaceuticals's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (PVCT) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Provectus Biopharmaceuticals (PVCT), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provectus Biopharmaceuticals Business Description

Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.